We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · January 04, 2020

Trifluridine/Tipiracil in Patients With Advanced, Refractory Biliary Tract Carcinoma

The Oncologist

 

Additional Info

The Oncologist
Phase II Trial of Trifluridine/Tipiracil in Patients With Advanced, Refractory Biliary Tract Carcinoma
Oncologist 2019 Dec 11;[EPub Ahead of Print], S Chakrabarti, TJ Zemla, DH Ahn, FS Ou, B Fruth, MJ Borad, ML Hartgers, J Wessling, RL Walkes, SR Alberts, RR McWilliams, MC Liu, LM Durgin, TS Bekaii-Saab, A Mahipal

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading